---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-075821"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:18:32.635745+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Amylyx appoints Karen Firestone to board of directors, effective March 16, 2023

## Summary
- Karen Firestone appointed as Class I director effective March 16, 2023.
- Will serve on Audit Committee and Nominating and Corporate Governance Committee.
- Eligible for annual cash retainer of $45,000 plus committee retainer fees.
- Granted initial option for 27,403 shares; one-third vests in 1 year, balance over 2 years.
- Director compensation policy amended January 20, 2023, filed as exhibit.

## SEC filing metadata
- accession: 0001193125-23-075821
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312523075821/0001193125-23-075821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312523075821/d452110d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-075821
- JSON: https://secwatch.observer/filing/0001193125-23-075821.json
- Plain text: https://secwatch.observer/filing/0001193125-23-075821.txt

## Key facts
- Executive change
  Karen Firestone was appointed as Director at Amylyx Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Karen Firestone to fill the vacancy on the Board as a Class I director, effective as of March 16, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000119312523075821/0001193125-23-075821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.